Saturday, 31 October 2026European Markets

CASINO GUICHARD Shares Plummet 30% In 10 Sessions: What's Happening?

Loading stream...

(vianews) - casino guichard dive 30.48% in 10 sessions; cac 40 increases by 0.62% shares of casino guichard (cac 40: co.pa) have experienced an astounding decline over the past ten sessions, falling by 30.48% from eur0.93 to eur0.65. opening at eur0.66, they reached their lowest intraday price before closing at eur0.64. this precipitous fall follows five consecutive sessions of losses for this stock; nevertheless, cac 40 index experienced positive trend by rising 0.62% to eur7,3112.99. casino guichard's recent performance has been marked by a sharp downward trajectory, falling 94.74% below its 52-week high of eur12.17 and sparking widespread concern from investors who now closely track its performance and potential catalysts for a turnaround. at present, the 50-day moving average has fallen below its 200-day moving average (eur0.92). this downward crossover may signal further bearish movement in the near term. traders must keep an eye out for earnings reports and key economic indicators to gauge a company's financial health and assess any possible chances for recovery.

about casino guichard

casino, guichard-perrachon s.a. was established in france in 1898, and today stands as a leading food retailer throughout france, latin america, and internationally. offering hypermarkets, supermarkets, shopping malls, e-commerce sites, convenience stores, discount stores, cash and carry stores and service stations among its diverse portfolio of stores - hypermarkets to supermarkets to shopping malls to e-commerce sites to cash and carry stores - casino is a pillar in food retailing as well as banking operations within banking, digital marketing activities such as banking digital marketing real estate asset management property development energy related activities among others - rallye sa holds ownership and headquarters of casino is saint etienne, france

yearly analysis

here is an investment forecast for investors looking into casino guichard shares: * current stock price: eur0.65, 52-week low: eur0.70 and yearly top value = not available, yearly bottom value = eur0.70 are some key data points from an anticipated sales growth perspective for this and next years respectively. as the stock price has recently fallen below its 52-week low and sales growth projections for both this and next year are negative, it may not be wise for investors to invest in casino guichard at this time. they should carefully examine its fundamentals and future potential before making any investment decisions.

technical analysis

casino guichard's stock has been on an increasingly downward trajectory, as evidenced by its current price of eur0.42, which lies far below both its 50-day and 200-day moving averages of eur1.13 and eur4.64, indicating an ongoing downtrend. notable about this stock's trading volume of 254,240 is that it represents 54.83% below its 118,4450 average volume - suggesting there may be limited buyer interest at present. furthermore, intraday volatility of this stock has been high with its current intraday variation average being negative 7.25% for each week, month, and quarter over this timeframe being 7.25%, 1.41%, and positive 4.98%, respectively. furthermore, its highest average amplitude volatility ranged between 7.25% (week), 4.21% (month), and 4.98% (quarter). according to the stochastic oscillator, casino guichard's stock may currently be overbought (>=80), signalling an imminent correction or pullback in price. overall, casino guichard's stock is in an unfavorable position, so investors should proceed with caution before making any investment decisions in this stock. wait for a more favorable market trend before considering investing.

quarter analysis

casino guichard's sales growth projection for the next quarter stands at negative 11.2%, signalling an expected decrease in revenue and perhaps raising alarm among investors as negative growth may indicate less demand for its products or services. additionally, year-on-year quarterly revenue growth has decreased by 5% over the last twelve trailing months compared to prior periods, suggesting that revenue is not growing as quickly. this may be an indicator that there may be challenges involved with growing its business. casino guichard's investment outlook appears to be negative based on available data. investors must carefully consider this data alongside other elements such as its financials, management team and industry trends before making any definitive investment decisions.

equity analysis

based on this information, casino guichard currently boasts an eps of eur-20.53 for the trailing twelve months - this indicates that shareholders are not currently making profits and thus serving as an indicator for potential investors that the company may not be financially secure or profitable in the short-term. furthermore, the company's return on equity (roe) over the last twelve months stands at negative -65.71% - suggesting it has failed to generate profits relative to shareholder's equity - an indicator of profitability. a negative roe can indicate that its assets may not be effectively utilized to bring profits for shareholders. based on these financial indicators, it may not be wise for investors to invest in casino guichard at this time. potential investors should conduct further financial analysis and research prior to making any investment decisions.

more news about casino guichard (co.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com